176 related articles for article (PubMed ID: 1828740)
1. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
[TBL] [Abstract][Full Text] [Related]
2. Effects of intensive dietary treatment on insulin-stimulated skeletal muscle glycogen synthase activation and insulin secretion in newly presenting type 2 diabetic patients.
Johnson AB; Argyraki M; Thow JC; Broughton D; Jones IR; Taylor R
Diabet Med; 1990 Jun; 7(5):420-8. PubMed ID: 2142039
[TBL] [Abstract][Full Text] [Related]
3. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
Vestergaard H; Lund S; Bjørbaek C; Pedersen O
Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
[TBL] [Abstract][Full Text] [Related]
4. In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment.
Bak JF; Møller N; Schmitz O; Saaek A; Pedersen O
Diabetologia; 1992 Aug; 35(8):777-84. PubMed ID: 1511806
[TBL] [Abstract][Full Text] [Related]
5. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
6. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients.
Bak JF; Schmitz O; Sørensen NS; Pedersen O
Diabetes; 1989 Nov; 38(11):1343-50. PubMed ID: 2559864
[TBL] [Abstract][Full Text] [Related]
7. Impaired activation of skeletal muscle glycogen synthase in non-insulin-dependent diabetes mellitus is unrelated to the degree of obesity.
Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
Metabolism; 1991 Mar; 40(3):252-60. PubMed ID: 1900343
[TBL] [Abstract][Full Text] [Related]
8. Hyperglycaemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with type 2 (non-insulin-dependent) diabetes mellitus.
Vaag A; Damsbo P; Hother-Nielsen O; Beck-Nielsen H
Diabetologia; 1992 Jan; 35(1):80-8. PubMed ID: 1541385
[TBL] [Abstract][Full Text] [Related]
9. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.
Johnson AB; Webster JM; Sum CF; Heseltine L; Argyraki M; Cooper BG; Taylor R
Metabolism; 1993 Sep; 42(9):1217-22. PubMed ID: 8412779
[TBL] [Abstract][Full Text] [Related]
10. Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy.
Wing JR; Panz VR; Joffe BI; Seftel HC
Diabet Med; 1993; 10(1):50-5. PubMed ID: 8435988
[TBL] [Abstract][Full Text] [Related]
11. Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
Donatelli M; Sinagra D; Russo V; Bucalo ML; Giardina E; Cerasola GA; Bompiani G
Pharmatherapeutica; 1985; 4(2):69-75. PubMed ID: 3903780
[TBL] [Abstract][Full Text] [Related]
12. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
13. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Ligtenberg JJ; Reitsma WD; van Haeften TW
Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
[TBL] [Abstract][Full Text] [Related]
14. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Matthews DR; Boland O
Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
[TBL] [Abstract][Full Text] [Related]
15. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
Ammari F; Davies MJ; Koppiker N; Gregory R; Burden AC
Diabet Med; 1999 Feb; 16(2):142-6. PubMed ID: 10229308
[TBL] [Abstract][Full Text] [Related]
16. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
Noury J; Nandeuil A
Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
[TBL] [Abstract][Full Text] [Related]
17. Diet only or diet and sulfonylureas in mild type II diabetes (NIDDM)? Pathophysiologic and therapeutic implications.
Sinay IR; Arias P; Schnitman MA; Damilano SA; Faingold MC; Moguilevsky JA
Acta Diabetol Lat; 1988; 25(4):289-97. PubMed ID: 3072813
[TBL] [Abstract][Full Text] [Related]
18. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus.
Damsbo P; Vaag A; Hother-Nielsen O; Beck-Nielsen H
Diabetologia; 1991 Apr; 34(4):239-45. PubMed ID: 1906024
[TBL] [Abstract][Full Text] [Related]
19. Liver and muscle insulin sensitivity, glycogen concentration and glycogen synthase activity in a rat model of non-insulin-dependent diabetes.
Kruszynska YT; Home PD
Diabetologia; 1988 May; 31(5):304-9. PubMed ID: 3135217
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
van der Wal PS; Heine RJ
Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
